Abstract
Background: Ruxolitinib is a selective JAK1/2 inhibitor approved by the FDA for myelofibrosis in 2014 and nowadays, comprehensive investigations on the potential of the agent as a targeted therapy for haematological malignancies are on the rise. In multiple myeloma which is a cancer of plasma cells, the Interleukin- 6/JAK/STAT pathway is emerging as a therapeutic target since the overactivation of the pathway is associated with poor prognosis.
Objective: In this study, our purpose was to discover the potential anticancer effects of ruxolitinib in ARH-77 multiple myeloma cell line compared to NCI-BL 2171 human healthy B lymphocyte cell line.
Methods: Cytotoxic effects of ruxolitinib in ARH-77 and NCI-BL 2171 cells were determined via WST-1 assay. The autophagy mechanism induced by ruxolitinib measured by detecting autophagosome formation was investigated. Apoptotic effects of ruxolitinib were analyzed with Annexin V-FITC Detection Kit and flow cytometry. We performed RT-qPCR to demonstrate the expression changes of the genes in the IL-6/JAK/STAT pathway in ARH-77 and NCI-BL 2171 cells treated with ruxolitinib.
Results: We identified the IC50 values of ruxolitinib for ARH-77 and NCI-BL 2171 as 20.03 and 33.9μM at the 72nd hour, respectively. We showed that ruxolitinib induced autophagosome accumulation by 3.45 and 1.70 folds in ARH-77 and NCI-BL 2171 cells compared to the control group, respectively. Treatment with ruxolitinib decreased the expressions of IL-6, IL-18, JAK2, TYK2, and AKT genes, which play significant roles in MM pathogenesis.
Conclusion: All in all, ruxolitinib is a promising agent for the regulation of the IL-6/JAK/STAT pathway and interferes with the autophagy mechanism in MM.
Keywords: Ruxolitinib, multiple myeloma, autophagy, Interleukin-6, JAK, STAT.
Graphical Abstract
[http://dx.doi.org/10.3322/caac.21332 ] [PMID: 26742998]
[http://dx.doi.org/10.1038/nrdp.2017.46 ] [PMID: 28726797]
[http://dx.doi.org/10.1053/j.seminoncol.2016.11.004 ] [PMID: 28061985]
[PMID: 24130968]
[http://dx.doi.org/10.1042/BST20140126 ] [PMID: 25109961]
[PMID: 10345500]
[http://dx.doi.org/10.1532/IJH97.04107 ] [PMID: 15540896]
[http://dx.doi.org/10.1038/s41388-017-0046-6] [PMID: 29255248]
[http://dx.doi.org/10.1038/sj.cdd.4400950 ] [PMID: 11965491]
[http://dx.doi.org/10.1038/nrd3652 ] [PMID: 22293561]
[http://dx.doi.org/10.1242/jcs.00963 ] [PMID: 15020666]
[http://dx.doi.org/10.3389/fonc.2018.00287 ] [PMID: 30109213]
[http://dx.doi.org/10.18632/oncotarget.21951 ] [PMID: 29262601]
[http://dx.doi.org/10.1038/nrclinonc.2018.8 ] [PMID: 29405201]
[http://dx.doi.org/10.1200/JCO.2010.31.8907 ] [PMID: 22355058]
[http://dx.doi.org/10.1038/sj.leu.2403970 ] [PMID: 16239913]
[http://dx.doi.org/10.1182/blood-2003-04-1048 ] [PMID: 12969979]
[http://dx.doi.org/10.1034/j.1600-065X.2003.00041.x ] [PMID: 12846807]
[http://dx.doi.org/10.1097/MOH.0000000000000259 ] [PMID: 27101529]
[http://dx.doi.org/10.1016/S0145-2126(03)00261-3] [PMID: 14687621]
[http://dx.doi.org/10.1016/j.ccell.2018.02.007 ] [PMID: 29551594]
[http://dx.doi.org/10.1182/blood.V124.21.5717.5717]
[http://dx.doi.org/10.3748/wjg.v20.i4.1074 ] [PMID: 24574781]
[http://dx.doi.org/10.1186/1476-4598-11-58] [PMID: 22909061]
[http://dx.doi.org/10.3389/fonc.2016.00142 ] [PMID: 27379204]
[PMID: 11118064]
[http://dx.doi.org/10.1038/sj.onc.1204833 ] [PMID: 11593406]
[http://dx.doi.org/10.1007/s13277-015-3947-4 ] [PMID: 26298727]
[http://dx.doi.org/10.1016/j.ccr.2013.02.017 ] [PMID: 23541952]
[http://dx.doi.org/10.1038/srep15701 ] [PMID: 26549519]
[http://dx.doi.org/10.1016/j.leukres.2017.06.002 ] [PMID: 28599191]